research use only
Cat.No.S7921
| Related Targets | p38 MAPK Raf JNK MEK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase |
|---|---|
| Other ERK Inhibitors | SCH772984 Ravoxertinib (GDC-0994) Ulixertinib (BVD-523) Temuterkib (LY3214996) FR 180204 XMD8-92 VX-11e AZD0364 (ATG-017) ERK5-IN-1 MK-8353 (SCH900353) |
|
In vitro |
DMSO
: 89 mg/mL
(200.21 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 444.53 | Formula | C26H28N4O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 181223-80-3 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | COC1=CC2=C(C=C1)NC=C2C=C3C4=C(C=CC(=C4)NC(=O)CCN5CCCCC5)NC3=O | ||
| Targets/IC50/Ki |
ERK
(in HEK293 cells) 0.5 μM
|
|---|---|
| In vitro |
DEL-22379 inhibits ERK dimerization without affecting its phosphorylation. In a panel of human cell lines harboring mutant BRAF (V600E) or RAS (Q61L or G12V), this compound shows potent anti-proliferative effects, and induces apoptosis.
|
| Kinase Assay |
ERK dimerization assay
|
|
Compound screening is performed in HEK293T cells treated with the potential inhibitors (10 μM) for 30 min before EGF stimulation. Cellular lysates are tested for ERK dimerization by native PAGE and p-ERK evaluation of the potential positives. In vitro ERK dimerization is assayed using GST-MEK1 ΔN EE purified from bacteria, bound to glutathione sepharose beads, and incubated with 25 μg/ml of purified His-ERK2 plus increasing concentrations of this compound. Western blotting, kinase assays, and luciferase assays are also performed. In silico docking of this compound is carried out with the modeling tools provided by the OpenEye package (v. 2.1).
|
|
| In vivo |
DEL-22379 (15 mg/kg, i.p.) prevents tumor growth and metastasis in mice bearing A375 (BRAF mutant) and HCT116 (KRAS mutant) tumors, but this compound fails to prevent the formation of tumors in mice injected with CHL cells (WT/WT).
|
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.